EQT Life Sciences — 2020 Investments

2 investments dated 2020 · listed companies and verified rows first · show all

Kinaset Therapeuticskinasettherapeutics.com in 𝕏Jul 2020 · $103M✓ verified

Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation.

BiotechHealthtechMedfield, US

Roger Heerman(Chief Business/Operating Officer / Co-Founder)inFrazer Morgan(Chief Development Officer / Co-Founder)inRobert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher O’Brien(Chief Medical Officer)

Board Jamil Beg(Director of the Issuer)inTom King(Director of the Issuer)

Co-investors5AM Ventures Atlas Venture RA Capital Gimv Sixty Degree Capital Vivo Capital +3 more

Imcheckimchecktherapeutics.com inSep 2020acquired by Clementia

ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation.

BiotechHealthtech

Daniel Olive(Founder)

Co-investorsAgent Capital Andera Partners Kurma Partners Pfizer Venture Investments Pureos Bioventures Alexandria +4 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.